We strive to relieve patients from the burdens of itch, pain, and epilepsy.
Our Therapeutic Focus
NeuroCycle Therapeutics is developing its lead candidate, NCT10004, as a first-in-class, orally administered treatment of itch - particularly itch related to atopic dermatitis. NCT10004 quickly reduced itch in preclinical models and is expected to be broadly active across multiple pruritic indications including atopic dermatitis.
NeuroCycle Therapeutics, Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of small-molecule drugs that target the central nervous system.
Our goal is to maximize the humanitarian impact and commercial potential of our innovative technology by targeting both common, highly prevalent disorders with large unmet medical needs, and orphan indications neglected by large pharmaceutical companies. This approach has tremendous potential to bring positive change to our world and impact patients’ lives.